ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1002

Survival and Years of Potential Life Lost in Connective Tissue Disease and Vasculitis; Data from the Norwegian Connective Tissue Diseases and Vasculitis Registry (NOSVAR)

Torhild Garen1, Karoline Lerang1, Anna Maria Hoffmann-Vold2, Helena Andersson1, Øyvind Midtvedt1, Karin Kilian1, Ragnar Gunnarsson1, Birgir Gudbrandsson1, Gudrun Norby1, Oyvind Molberg2 and Øyvind Palm1, 1Department of Rheumatology, Oslo University Hospital, Oslo, Norway, OSLO, Norway, 2Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: autoimmune diseases, morbidity and mortality and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Epidemiology and Public Health Poster II: Rheumatic Diseases Other than Rheumatoid Arthritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Survival is decreased in patients with connective tissue diseases (CTDs) and vasculitis, however few studies have compared the mortality between the specific diseases prospectively by similar methods for patient’s selection. Here, we aimed to compare survival, standard mortality rates (SMR) and premature mortality between diagnoses of CTDs and vasculitis .

Methods:

All patients included in NOSVAR diagnosed from January 1, 1999 to December 31, 2016, in total 2148 patients were followed up until death or study end. Fifteen controls matched for each individual patient for year of birth, sex and residence area was randomly selected from the Norwegian Central Public Population Register. All controls were alive at time of patients diagnosis. Kaplan-Meier survival probabilities and curves were used to determine survival, and the difference between patients and controls was estimated by the log-rank test (Mantel Cox). In the Standardized mortality ratio (SMR) the number of deaths was divided by number of years of observation for each diagnosis and calculated as the ratio between the observed and expected numbers of death. The years of potential life lost (YPLL) was defined as the years a person would have lived if he or she had not died prematurely (here defined as 60 years of age). The YPLL for each death in patients are summed to represent the total years of potential life lost for all patients in each patient-group. The YPLL (60) rate is found by dividing YPLL by years of observation under the age of 60 in each group.

Results:

During a mean (SD) follow-up time of 9,2 years (4,7), 280/2148 (13%) patients deceased compared to 2885/32186 (9%) of the controls (p<0.001). Patient’s characteristics and demographics are shown in Table 1. Compared to controls, the lowest 5-and 10 years survival was seen in diffuse cutaneous systemic sclerosis (dcSSc) (79 % and 60%), (p<0.001), Antisynthetase syndrome (86% and 73%), (p<0.001), and limited systemic sclerosis, (89% and 75%), (p<0.001) Figure 1). For ANCA vasculitis and controls 5 years survival was 91% vs 95% and 10 years survival was 80 % vs 87%., (p=0.030). Highest SMR was observed for dSSc (5,8) and Antisynthetase syndrome (4,1)(Figure 2) The sum of YPLL60 among patients was 493 years and in matched controls 115 years, indicating a four-fold increase in premature deaths among the patients. The mean YPLL60 was highest in SLE and Takayasu with 19 and 15 years lost, respectively. Both lcSSc and dcSSc had a mean of 7 years lost YPLL60. The ranking of annual rate of YPLL60 for each disease is shown in (Figure 3)

Conclusion:

We show that there is a difference in survival, mortality and YPLL60 among the different CTDs and vasculitis. Methods used supplement each other and highlights the different aspects of outcome among the diagnoses. Systemic sclerosis and Antisynthetase syndrome had the lowest 5 and 10 years survival and the highest rate of premature mortality, but the mean loss of years before 60 years of age were higher in individuals with Takayasus and SLE.


Disclosure: T. Garen, None; K. Lerang, None; A. M. Hoffmann-Vold, None; H. Andersson, None; Ø. Midtvedt, None; K. Kilian, None; R. Gunnarsson, None; B. Gudbrandsson, None; G. Norby, None; O. Molberg, None; Ø. Palm, None.

To cite this abstract in AMA style:

Garen T, Lerang K, Hoffmann-Vold AM, Andersson H, Midtvedt Ø, Kilian K, Gunnarsson R, Gudbrandsson B, Norby G, Molberg O, Palm Ø. Survival and Years of Potential Life Lost in Connective Tissue Disease and Vasculitis; Data from the Norwegian Connective Tissue Diseases and Vasculitis Registry (NOSVAR) [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/survival-and-years-of-potential-life-lost-in-connective-tissue-disease-and-vasculitis-data-from-the-norwegian-connective-tissue-diseases-and-vasculitis-registry-nosvar/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/survival-and-years-of-potential-life-lost-in-connective-tissue-disease-and-vasculitis-data-from-the-norwegian-connective-tissue-diseases-and-vasculitis-registry-nosvar/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology